AUTHOR INDEX

Volume 73 • 1997

Abe, N. *See* Ashizawa, N.
Abiko, Y. *See* Hoque, A.N.E.
Akaike, A. *See* Kume, T.
Akaike, N. *See* Ashizawa, N.
Aotsuka, T. *See* Ashizawa, N.
Arai, I., Shimazoe, T., Shibata, S., Inoue, H., Yoshimatsu, A. and Watanabe, S.
Dopamine release in sensitized rats 243
Asano, K. *See* Katayama, K.
Asano, S. *See* Satoh, H.
Ashizawa, N., Yoshida, M., Sugiyama, Y., Akaike, N., Ohbayashi, S., Aotsuka, T., Abe, N., Fukushima, K. and Matsuura, A.
Novel aldose reductase inhibitor, GP-1447 133
Atsuta, Y., *See* Matsunaga, M.

Chang, C.-W., Ko, F.-N., Su, M.-J., Wu, Y.-C. and Teng, C.-M.
Ocoteine, an α_1-adrenoceptor antagonist 207

Domoto, H. *See* Moriyama, M.

Endo, T. *See* Taniguchi, H.
Eto, K. *See* Kanda, M.
Etoh, H. *See* Matsunaga, M.

Folkman, J. *See* Satoh, H.
Fujii, T. *See* Yamaguchi, N.
Fujimoto, K. *See* Yamaguchi, N.
Fujita, T. *See* Kume, T.
Fukuda, T. *See* Katayama, K.
Fukushima, K. *See* Ashizawa, N.
Fukuta, T. *See* Nitta, A.
Furukawa, M. *See* Ikeda, K.
Furuno, K. *See* Moriyama, M.

Geng, M.-Y., Saito, H. and Nishiyama, N.
Neuroprotective effect of ifenprodil 97
Gomita, Y. *See* Moriyama, M.

Haga, K. *See* Katayama, K.
Hara, A. *See* Hoque, A.N.E.
Hasegawa, T. *See* Nitta, A.
Hashimoto, K. *See* Kanda, M.
Hashizume, H. *See* Hoque, A.N.E.
Hata, F. *See* Niioka, S.
Hayashi, K., Nagamatsu, T., Oka, T. and Suzuki, Y.
Antinephritic effect of ONO-1301 73
Hayashi, N. *See* Okada, M.
Hayashi, T. *See* Kamata, K.
Hoque, A.N.E., Hoque, N., Hara, A., Hashizume, H., Ichihara, K. and Abiko, Y.
K-7259 on ischemia and reperfused heart 365
Hoque, N. *See* Hoque, A.N.E.

Ichihara, K. *See* Hoque, A.N.E.
Ichimaru, Y. *See* Mori, T.
Iizumi, Y. *See* Kashiwa, M.
Ikeda, K., Furukawa, M., Tanno, N., Yamaya, M. and Takasaka, T.
Cl^- secretion by *Sai-rei-to* 29
Inada, I. *See* Satoh, H.
Inada, Y. *See* Kanagawa, R.
Inagaki, C. *See* Tanabe, T.
Inatomi, N. *See* Satoh, H.
Inoue, H. *See* Arai, I.
Inukai, T. *See* Okada, M.
Ishii, T. *See* Niioka, S.
Isohama, Y., Kumanda, Y., Tanaka, K., Kai, H., Takahama, K. and Miyata, T.
Dexamethasone and surfactant phosphatidylcholine secretion 163
Ito, N. *See* Kashiwa, M.
Iwasaki, T. *See* Nakamura, K.

Kadota, S. *See* Matsumoto, K.
Kai, H. *See* Isohama, Y.
Kakiuchi, M., Ohashi, T., Musoh, K., Kawamura, K., Morikawa, K. and Kato, H.
Central effects of antiallergic agents 291
Kakuta, H. *See* Kashiwa, M.
Kamata, K., Hayashi, T. and Umeda, F.
CPA and pathology 247
Kanagawa, R., Wada, T., Sanada, T., Ojima, M. and Inada, Y.
Regional hemodynamic effects of TCV-116 185
Kanai, K. *See* Matsunaga, M.
Kanda, M., Eto, K., Tanabe, N., Sugiyama, A., Hashimoto, K. and Ueno, A.
Aldose reductase on diabetic M receptors 221
Kaneko, S. *See* Kume, T.
Kangawa, K. *See* Okamura, T.
Kashiwa, M., Masuyama, Y., Miyauchi, H., Uchida, T., Naganuma, S., Kakuta, H., Terada, M., Kiriyama, T., Matsuda, K., Ito, N., Iizumi, Y. and Takenaka, T.
ACAT inhibitor and diarrhea 41
Katayama, K., Asano, K., Haga, K. and Fukuda, T.
The binding affinity of azasetron 357
Kato, H. *See* Kakiuchi, M.
Kato, K. *See* Satoh, H.
Kato, M. *See* Matsumoto, Y.
Kato, R. *See* Nishikawa, K.
Kawamura, K. *See* Kakiuchi, M.
Kawasaki, H. *See* Moriyama, M.
Kawashima, K. *See* Yamaguchi, N.
Kawazura, H., Takahashi, Y., Shiga, Y., Shimada, F., Ohto, N. and Tamura, A.
Effect of MS-153 on brain ischemia 317
Kiriyama, T. *See* Kashiwa, M.
Kishi, M. *See* Niioka, S.
Ko, F.-N. *See* Chang, C.-W.
Kobayashi, S. *See* Tanaka, M.
Kohchiyama, H. *See* Kume, T.
Kohno, S. *See* Matsumoto, K.
Koike, K. *See* Takayanagi, I.
Koike, Y. *See* Yamamoto, Takatsugu
Kojima, S.
CGRP and NANC transmission 255
Kometani, M. *See* Okada, M.
Kumai, T. *See* Tanaka, M.
Kumanda, Y. *See* Isohama, Y.
Kume, E. *See* Taniguchi, H.

Kume, T., Kohchiyama, H., Nishikawa, H., Maeda, T., Kaneko, S., Akaike, A., Noda, N. and Fujita, T.
Neuroprotection by fetal calf serum 371
Kurihara, H. *See* Shinosaki, T.
Kuromi, H. and Seino, S.
Inhibition of glucose effect by suramin 179
Kurose, H. *See* Sato, Y.

Maeda, R. *See* Satoh, H.
Maeda, T. *See* Kume, T.
Masukawa, T. and Nakanishi, K.
Circadian variation of convulsion 175
Masuyama, Y. *See* Kashiwa, M.
Matsuda, K. *See* Kashiwa, M.
Matsumoto, K., Kohno, S., Tezuka, Y., Kadota, S. and Watanabe, H.
Angelica root and social isolation stress 353
Matsumoto, Y., Kato, M., Tamada, Y., Mori, H. and Ohashi, M.
Effects of *Sho-saiko-to* on keratinocytes 333
Matsunaga, M., Uemura, Y., Yonemoto, Y., Kanai, K., Etoh, H., Tanaka, S., Atsuta, Y., Nishizawa, Y. and Yamanishi, Y.
Transdermal eperisone as muscle relaxant 215
Matsuura, A. *See* Ashizawa, N.
Mineshita, S. *See* Yamamoto, Takatsugu
Misawa, M. and Sato, J.
NO and airway hyperresponsiveness 125
Mishima, K. *See* Tanabe, T.
Miyata, T. *See* Isohama, Y.
Miyauchi, H. *See* Kashiwa, M.
Mori, H. *See* Matsumoto, Y.
Mori, T., Murase, K., Tanaka, J. and Ichimaru, Y.
Interaction between D_1- and D_3-agonists 251
Morikawa, K. *See* Kakiuchi, M.
Moriyama, M., Yamashita, S., Furuno, K., Sato, T., Domoto, H., Yamatogi, Y., Kawasaki, H. and Gomita, Y.
Lactation and plasma phenobarbital concentrations 191
Murakami, I. *See* Satoh, H.
Murase, K. *See* Mori, T.
Murayama, T. *See* Yamada, T.
Musoh, K. *See* Kakiuchi, M.

Nabeshima, T. *See* Nitta, A.
Nagamatsu, T. *See* Hayashi, K.
Naganuma, S. *See* Kashiwa, M.
Nagao, T. *See* Sato, Y.
Nagasaki, M. *See* Taniguchi, H.
Nagaya, H. *See* Satoh, H.
Nagumo, H. *See* Nishikawa, K.
Nakamura, K., Ohyanagi, M. and Iwasaki, T.
mRNA for β-adrenoceptor in ischemia 23
Nakanishi, K. *See* Masukawa, T.
Nakao, K. *See* Okada, M.
Nakaya, S. *See* Tanaka, M.
Niioka, S., Takeuchi, T., Kishi, M., Ishii, T., Nishio, H., Takewaki, T. and Hata, F.
NANC relaxation in rat jejunum 155
Nishikawa, H. *See* Kume, T.
Nishikawa, K., Yamamoto, S., Nagumo, H. and Kato, R.
PKCζ activation by Ca^{2+}-induced differentiation 171
Nishio, H. *See* Niioka, S.
Nishiyama, N. *See* Geng, M.-Y.
Nishizawa, Y. *See* Matsunaga, M.
Nitta, A., Fukuta, T., Hasegawa, T. and Nabeshima, T.
Toxicity of β-amyloid protein in vivo 51
Noda, N. *See* Kume, T.
Nomura, Y. *See* Yamada, T.

Ogawa, R. *See* Tanabe, T.
Ohashi, M. *See* Matsumoto, Y.
Ohashi, T. *See* Kakiuchi, M.
Ohbayashi, S. *See* Ashizawa, N.
Ohizumi, Y.
Pharmacological tools from natural resources 263
Ohto, N. *See* Kawazura, H.
Ohyanagi, M. *See* Nakamura, K.
Ojima, M. *See* Kanagawa, R.
Oka, T. *See* Hayashi, K.
Okada, M., Hayashi, N., Kometani, M., Nakao, K. and Inukai, T.
Effect of estradiol on TST and FST 93
Okamura, T. *See* Shiraishi, S.
Okamura, T., Zhang, J.-X., Kangawa, K. and Toda, N.
Inhibition by AM of adrenergic function 259
Okayasu, A. *See* Takayanagi, I.
Osaki, T. *See* Yoneda, K.
Otani, H. *See* Tanabe, T.

Saito, H. *See* Geng, M.-Y.
Sanada, T. *See* Kanagawa, R.
Sanaka, M. *See* Yamamoto, Takatsugu
Sato, F. *See* Satoh, H.
Sato, J. *See* Misawa, M.
Sato, T. *See* Moriyama, M.
Sato, Y., Kurose, H. and Nagao, T.
Desensitization of cardiac β-adrenoceptors 325
Satoh, H., Asano, S., Maeda, R., Murakami, I., Inada, I., Sato, F. and Shino, A.
Prevention of ulcer relapse by bFGF 229
Satoh, H., Sato, F., Takami, K. and Szabo, S.
Ulcerative colitis by sulfhydryl blocker 299
Satoh, H., Shino, A., Sato, F., Asano, S., Murakami, I., Inatomi, N., Nagaya, H., Kato, K., Szabo, S. and Folkman, J.
Role of bFGF in healing of gastric ulcers 59
Satoh, M. *See* Takayanagi, I.
Seino, S. *See* Kuromi, H.
Shibasaki, K., Takizawa, K., Uchida, W. and Takenaka, T.
Ca^{2+} antagonist with β-blocking activity 113
Shibata, S. *See* Arai, I.
Shiga, Y. *See* Kawazura, H.
Shikano, T. *See* Taniguchi, H.
Shimada, F. *See* Kawazura, H.
Shimakura, K. *See* Yamamoto, Takatsugu
Shimazoe, T. *See* Arai, I.
Shino, A. *See* Satoh, H.
Shinosaki, T., Takagawa, I., Sunagawa, N., Yonetani, Y. and Kurihara, H.
Effect of lisinopril on PAN nephrosis 337
Shiraishi, S., Okamura, T. and Toda, N.
β_1-receptor in hepatic arterial relaxation 101
Su, M.-J. *See* Chang, C.-W.
Sugiyama, A. *See* Kanda, M.
Sugiyama, Y. *See* Ashizawa, N.
Sunagawa, N. *See* Shinosaki, T.
Suzuki, T. *See* Yamaguchi, N.
Suzuki, Y. *See* Hayashi, K.
Szabo, S. *See* Satoh, H.

Takagawa, I. *See* Shinosaki, T.
Takahama, K. *See* Isohama, Y.
Takahashi, Y. *See* Kawazura, H.
Takami, K. *See* Satoh, H.
Takasaka, T. *See* Ikeda, K.
Takayanagi, I., Koike, K., Satoh, M. and Okayasu, A.
Drug receptor mechanisms 1

Takenaka, T. *See* Kashiwa, M.
—— *See* Shibasaki, K.
Takeuchi, T. *See* Niioka, S.
Takewaki, T. *See* Niioka, S.
Takizawa, K. *See* Shibasaki, K.
Tamada, Y. *See* Matsumoto, Y.
Tamura, A. *See* Kawazura, H.
Tanabe, N. *See* Kanda, M.
Tanabe, T., Otani, H., Mishima, K., Ogawa, R. and Inagaki, C.
Oxyradical production in synovial cells 347
Tanaka, J. *See* Mori, T.
Tanaka, K. *See* Isohama, Y.
Tanaka, M., Nakaya, S., Watanabe, M., Kumai, T., Tateishi, T. and Kobayashi, S.
Estrogen replacement on aorta ACE activity 361
Tanaka, S. *See* Matsunaga, M.
Taniguchi, H., Yomota, E., Kume, E., Shikano, T., Endo, T. and Nagasaki, M.
Effect of T-0632 on acute pancreatitis 105
Tanno, N. *See* Ikeda, K.
Tateishi, T. *See* Tanaka, M.
Teng, C.-M. *See* Chang, C.-W.
Terada, M. *See* Kashiwa, M.
Tezuka, Y. *See* Matsumoto, K.
Toda, N. *See* Okamura, T.
—— *See* Shiraishi, S.

Uchida, T. *See* Kashiwa, M.
Uchida, W. *See* Shibasaki, K.
Uemura, Y. *See* Matsunaga, M.
Ueno, A. *See* Kanda, M.
Ueta, E. *See* Yoneda, K.
Umeda, F. *See* Kamata, K.

Wada, T. *See* Kanagawa, R.
Wang, L. *See* Yamamoto, Takatsugu
Warashina, A.
Indomethacin effects on CA secretion 197
Watanabe, H. *See* Matsumoto, K.
Watanabe, M. *See* Tanaka, M.
Watanabe, S. *See* Arai, I.
Wu, Y.-C. *See* Chang, C.-W.

Yamada, T., Murayama, T. and Nomura, Y.
Muscarinic receptors on thymocytes 311
Yamaguchi, N., Fujimoto, K., Fujii, T., Suzuki, T. and Kawashima, K.
Antihypertensive effect of YM358 in SHRSP 83
Yamamoto, S. *See* Nishikawa, K.
Yamamoto, Takatsugu, Wang, L., Shimakura, K., Sanaka, M., Koike, Y. and Mineshita, S.
Angiotensin and pulmonary edema 33
Yamamoto, Tetsuya *See* Yoneda, K.
Yamanishi, Y. *See* Matsunaga, M.
Yamashita, S. *See* Moriyama, M.
Yamatogi, Y. *See* Moriyama, M.
Yamaya, M. *See* Ikeda, K.
Yomota, E. *See* Taniguchi, H.
Yoneda, K., Yamamoto, Tetsuya, Ueta, E. and Osaki, T.
Suppression of azelastine of NF-κB activation 145
Yonemoto, Y. *See* Matsunaga, M.
Yonetani, Y. *See* Shinosaki, T.
Yoshida, M. *See* Ashizawa, N.
Yoshimatsu, A. *See* Arai, I.

Zhang, J.-X. *See* Okamura, T.

SUBJECT INDEX

Volume 73 • 1997

Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor 41
Adenylyl cyclase 325
Adrenal chromaffin cell 197
Adrenergic neurotransmission 259
α_1-Adrenoceptor 1
α_1-Adrenoceptor antagonist 207
β-Adrenoceptor 23, 163, 325
β_1-Adrenoceptor 101
β-Adrenoceptor antagonist 325
Adrenomedullin 259
Afterload 33
Airway hyperresponsiveness 125
Aldose reductase inhibitor 133, 221
Alveolar type II cell 163
Alzheimer's disease 51
Amphoteric compound 291
Amyloid protein 51
Angelicae radix 353
Angiogenesis 59
Angiotensin II 33
Angiotensin II receptor antagonist 185
Angiotensin AT_1-receptor antagonist 83
Angiotensin-converting enzyme (ACE) 361
Anionic charge barrier 337
Antiallergic agent 291
Anti-glomerular basement membrane (GBM) nephritis 73
Antihypertensive effect 83, 113
Antiinflammatory drug 299
Aorta 361
Apamin-sensitive K^+ channel 155
Autocrine growth 333
Azasetron 357
Azelastine hydrochloride 145

Basal secretion 29
Basic fibroblast growth factor (bFGF) 59, 229
β_1-blocker 113
β cell 179
Bladder dome 221
Blood flow 185
Bradykinin 197

Ca^{2+}-induced differentiation 171
Caerulein 105
Calcitonin gene-related peptide (CGRP) 255
Calcium antagonist 113
cAMP 73
Candesartan cilexetil (TCV-116) 185
Cardiac ventricle 325
Cassytha filiformis 207
Cataract formation 133
Catecholamine secretion 197
Central nervous system penetraion 291
Cerebroprotection 317
β-Chloroethylamine 1
Cholecystokinin $(CCK)_A$ receptor 105
Cholesterol 41
Cholinergic neuron 51
Cholinergic neurotransmission 125
M_3-Cholinoceptor 1
Circadian variation 175
Cl^- secretion 29
Colon 255
Convulsion 175
Cultured keratinocyte 333
Cyclopiazonic acid 247
Cytokine 145

D_1-receptor agonist 251
D_3-receptor agonist 251
Depressor action 259
Desensitization of β-adrenoceptor 325
Diabetes 221, 247
Diabetic neuropathy 133
Diarrhea 41
Dinitrophenylated (DNP)-*Ascaris* 125
DNA fragmentation 311
Dopamine release 243
Drug receptor mechanism 1

Enalapril 185
Endothelium-derived relaxing factor 247
Enoxacin 175
Eperisone hydrochloride 215
Estrogen replacement therapy 361
N-Ethylmaleimide 299
Excitation-contraction coupling 263
Excitotoxic disorder 97

Fetal calf serum 371
bFGF mutein CS23 (TGP-580) 59, 229
Fibroblast growth factor (basic) (bFGF) 59, 229
Focal cerebral ischemia 317
Forced swimming test 93

Gastric ulcer 59
Gastric ulcer relapse 229
Glial fibrillary acidic protein 51
Glomerular sclerosis 337
Glucocorticoid 163
Glucose 179
Glutamate 371

Heart failure 33
Hepatic artery 101
Hippocampal cultured neuron 97
Histamine H_1-receptor 291
Histamine H_2-receptor antagonist 229
HSR-609 (3-[4-(8-fluoro-5,11-dihydro-benz[*b*]oxepino[4,3-*b*]pyridin-11-ylidene-piperidino]propionic acid dihydrate) 291
5-HT_3 receptor 357
Hybridization (*in situ*) 23
Hydrocortisone 311

Ifenprodil 97
Indomethacin 197
In situ hybridization 23
Intercollicular decerebrated rat rigidity model 215
Interleukin-1α 333
Iodoacetamide 299
Ion channel 263
Irreversible β-adrenoceptor antagonist 325
Ischemia 23, 317, 365
Isozyme 171

Jejunum 155

K-7259 (*N,N'*-bis[4-(3,4,5-trimethoxyphenyl)-butyl]homopiperazine dihydrochloride) 365
K^+ channel 155
Keratinocyte 333

Lactation 191
Learning and memory 51
Lisinopril 337
Losartan 33

M_3-cholinoceptor 1
Metabotropic glutamate receptor 243
Methamphetamine-induced sensitization 243
Middle cerebral artery occlusion 317
Motor activity 251
Motor nerve conduction velocity 133
MS-153 ((*R*)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline) 317
Mucociliary transport 29
Muscarine 197
Muscarinic receptor 221, 311
Muscle relaxant activity 215

Nephrosis 337
NF-κB 145
NIH Image program 215
Nitrergic dysfunction 125
Nitric oxide 125, 155, 371
Nitric oxide synthase 145
Nonadrenergic, noncholinergic (NANC) relaxation 155
Nonadrenergic noncholinergic (NANC) transmission 255
Norepinephrine 101

Ocoteine 207
ONO-1301 ([7,8-dihydro-5-[(*E*)-[[a-(3-pyridyl)benzylidene]aminooxy]ethyl]-1-naphtyloxy]acetic acid) 73
Otitis media with effusion 29
Ovariectomy 93
Oxyradical production 347

Pancreatic duct ligation 105

Pancreatitis 105
Pentobarbital sleep 353
Percutaneous administration 215
Pharmacokinetics 191
Pharmacological tool 263
Phenobarbital 191
Physiologically active substance 263
Plasma concentration 191
Polyol pathway 221
Protein kinase C 171, 347
Protein phosphorylation 263
Pulmonary edema 33
Pulmonary surfactant 163
Puromycin aminonucleoside nephrosis 337

Radiotelemetry 83
Rigidity model (rat) 215
mRNA 23
RNase protection assay 163

Sho-saiko-to 333
Short-circuit current 29
Signal transduction 1
Small intestine 357
Social isolation stress 353
Sorbitol 133
Spontaneously hypertensive rat 185
Stress 353
Striatal dopamine release 243
Stroke-prone spontaneously hypertensive rats 83
Sulfhydryl blocker 299
Suramin 179
Synovial cell 347

T-0509 ((−)-(*R*)-1-(3,4-dihydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino]ethanol hydrochloride) 325
T-0632 (sodium (*S*)-1-(2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinylcarbonyl)amino]-6-methoxy-2-oxo-1*H*-indole-3-propanoate) 105
Tail skin temperature 93
TCV-116 (candesartan cilexetil) 185
TGP-580 (bFGF mutein CS23) 59, 229
Therapeutic window 317
Thoracic aorta 207
Thymocyte 311

Ulcerative colitis model 299

Vascular cell adhesion molecule 73

Working rat heart 365

YM17E (1,3-bis[[1-cycloheptyl-3-(*p*-dimethylaminophenyl)ureido]methyl]benzene dihydrochloride) 41
YM358 (2,7-diethyl-5-[[2′-(1*H*-tetrazole-5-yl)biphenyl-4-yl]methyl]-5*H*-pyrazolo[1,5-*b*][1,2,4]triazole potassium salt) 83
YM430 (4(((*S*)-2-hydroxy-3-phenoxypropyl)amino)butyl methyl 2,6-dimethyl-((*S*)-4-(*m*-nitrophenyl))-1,4-dihydropyridine-3,5-dicarboxylate) 113